全文获取类型
收费全文 | 154篇 |
免费 | 14篇 |
专业分类
儿科学 | 4篇 |
妇产科学 | 4篇 |
基础医学 | 22篇 |
口腔科学 | 16篇 |
临床医学 | 8篇 |
内科学 | 42篇 |
皮肤病学 | 1篇 |
神经病学 | 9篇 |
特种医学 | 2篇 |
外科学 | 6篇 |
综合类 | 3篇 |
预防医学 | 19篇 |
眼科学 | 6篇 |
药学 | 14篇 |
肿瘤学 | 12篇 |
出版年
2022年 | 7篇 |
2021年 | 13篇 |
2020年 | 5篇 |
2019年 | 8篇 |
2018年 | 8篇 |
2017年 | 1篇 |
2016年 | 2篇 |
2015年 | 12篇 |
2014年 | 10篇 |
2013年 | 12篇 |
2012年 | 7篇 |
2011年 | 14篇 |
2010年 | 6篇 |
2009年 | 4篇 |
2008年 | 14篇 |
2007年 | 11篇 |
2006年 | 6篇 |
2005年 | 8篇 |
2004年 | 9篇 |
2003年 | 1篇 |
2002年 | 1篇 |
2001年 | 1篇 |
1998年 | 1篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1978年 | 2篇 |
1977年 | 1篇 |
1974年 | 1篇 |
1973年 | 1篇 |
排序方式: 共有168条查询结果,搜索用时 15 毫秒
1.
Edvardas Kaminskas Ann Farrell Sophia Abraham Amy Baird Li-Shan Hsieh Shwu-Luan Lee John K Leighton Hasmukh Patel Atiqur Rahman Rajeshwara Sridhara Yong-Cheng Wang Richard Pazdur 《Clinical cancer research》2005,11(10):3604-3608
PURPOSE: This article summarizes data submitted to the U.S. Food and Drug Administration for marketing approval of azacitidine as injectable suspension (Vidaza, Pharmion Corporation, Boulder, CO) for treatment of patients with myelodysplastic syndrome. EXPERIMENTAL DESIGN: In one phase 3 controlled trial, 191 study subjects were randomized to treatment with azacitidine or to observation; an additional 120 patients were treated with azacitidine in two phase 2 single arm studies. The primary efficacy end point was the overall response rate, defined as complete or partial normalization of peripheral blood counts and bone marrow blast percentages for at least 4 weeks. RESULTS: In the controlled trial, the overall response rate was 15.7% in the azacitidine treatment group; there were no responders in the observation group (P < 0.0001). Response rates were similar in the two single arm studies. During response patients stopped being red cell or platelet transfusion dependent. Median duration of responses was at least 9 months. An additional 19% of azacitidine-treated patients had less than partial responses, most becoming transfusion independent. The most common adverse events attributed to azacitidine were gastrointestinal, hematologic, local (injection site), and constitutional. There were no azacitidine-related deaths. CONCLUSIONS: On May 19, 2004 the U.S. Food and Drug Administration approved azacitidine as injectable suspension for treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia. Full prescribing information is available at http://www.fda.gov/cder/foi/label/2004/050794lbl.pdf. Azacitidine is the first agent approved for treatment of myelodysplastic syndrome. 相似文献
2.
Limas Kupcinskas Lone Rasmussen Laimas Jonaitis Gediminas Kiudelis Marianne Jørgensen Neringa Urbonaviciene Vytas Tamosiunas Juozas Kupcinskas Jolanta Miciuleviciene Edmundas Kadusevicius Douglas Berg Leif P. Andersen 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2013,121(5):431-436
The study evaluated the changes in the prevalence of Helicobacter pylori strains with primary resistance to antibiotics during the last 10 years in Lithuania. H. pylori susceptibilities to antibiotics were tested in 89 patients in 1998, in 81 patients in 2001 and in 90 patients in 2007/2008. Susceptibility to metronidazole, clarithromycin, amoxicillin and tetracycline was tested using E‐test or agar dilution method. Susceptibility to ciprofloxacin was only tested in 2007/2008. Data about utilization of all authorized and available on market macrolides and clindamycin in Lithuania during 2003–2007 were evaluated using WHO ATC/DDD methodology. A total of 260 H. pylori strains cultured from untreated adult patients were investigated. Primary resistance rates (1998, 2001 and 2007/2008) for metronidazole were 24.7%, 33.3%, and 35.6%, for clarithromycin 1.1%, 3.7%, and 3.3% and for tetracycline 0%, 2.5% and 0% respectively. No cases of amoxicillin resistance have been detected. The resistance rate for ciprofloxacin was 5.6% in 2007/2008. Data of total macrolides and clarithromycin utilization in Lithuania revealed that despite an increase of consumption of these drugs in Lithuania during 2003–2007 in 1.5 times, the total macrolide consumption remains one of the lowest in Europe. We have not observed any significant changes in the susceptibility of H. pylori to the most widely used antibiotics during the recent 10‐year period. The low resistance rate to clarithromycin might be related to the policy to avoid use of macrolides as first‐line treatment for pulmonary and other infections. 相似文献
3.
4.
Influence of Vertical Soft Tissue Thickness on Crestal Bone Changes Around Implants with Platform Switching: A Comparative Clinical Study 下载免费PDF全文
5.
6.
7.
Taylor RM Maaty WS Lord CI Hamilton T Burritt JB Bothner B Jesaitis AJ 《Molecular immunology》2007,44(4):625-637
The integral membrane protein flavocytochrome b (Cyt b) is the catalytic core of the NADPH oxidase complex, a multicomponent enzyme system that initiates a cascade of reactive oxygen species that play a critical role in innate immunity and vascular physiology. Epitope-mapped, monoclonal antibodies (mAb) that recognize the large (gp91phox) and small (p22phox) subunits of Cyt b provide valuable reagents that have been used to examine structural and mechanistic aspects of oxidase function. In the present study, the heavy and light chain variable region genes of the Cyt b-specific mAbs 44.1, NS5, and NL7 have been amplified by RT-PCR, cloned and subject to DNA sequence analysis. Since the 5' degenerate primer sets used for mAb gene amplification were observed to introduce extensive heterogeneity into the heavy and light chain FR1 regions, N-terminal protein sequence analysis was also conducted to obtain the correct amino acid sequence of this region. In order to confirm the identity of the cloned genes, intact mAbs were resolved by two-dimensional electrophoresis and subject to in-gel tryptic digestion for analysis by both MALDI and nanospray LC-MS/MS. Databases searches using the derived mAb sequences predicted residues comprising CDR loops, identified candidate germline genes, and showed the respective germline genes to accurately predict the N-terminal amino acid residues for each variable region. The above studies report the amino acid sequence of Cyt b-specific mAb variable region genes with high confidence and provide essential information for future efforts at Cyt b structure analysis by resonance energy transfer and X-ray crystallography. 相似文献
8.
Caroline E. Dale Jaroslav A. Hubacek Tom M. Palmer Hynek Pikhart Anne Peasey Annie Britton Pia Horvat Ruzena Kubinova Sofia Malyutina Andrzej Pajak Abdonas Tamosiunas Aparna Shankar Archana Singh‐Manoux Mikhail Voevoda Mika Kivimaki Aroon D. Hingorani Michael G. Marmot Juan P. Casas Martin Bobak 《Addiction (Abingdon, England)》2014,109(9):1462-1471
9.
Lucie Kalisova Jiri Raboch Alexander Nawka Gaia Sampogna Libor Cihal Thomas W. Kallert Georgi Onchev Anastasia Karastergiou Valeria del Vecchio Andrzej Kiejna Tomasz Adamowski Francisco Torres-Gonzales Jorge A. Cervilla Stephan Priebe Domenico Giacco Lars Kjellin Algirdas Dembinskas Andrea Fiorillo 《Social psychiatry and psychiatric epidemiology》2014,49(10):1619-1629
Purpose
This study aims to identify whether selected patient and ward-related factors are associated with the use of coercive measures. Data were collected as part of the EUNOMIA international collaborative study on the use of coercive measures in ten European countries.Methods
Involuntarily admitted patients (N = 2,027) were divided into two groups. The first group (N = 770) included patients that had been subject to at least one of these coercive measures during hospitalization: restraint, and/or seclusion, and/or forced medication; the other group (N = 1,257) included patients who had not received any coercive measure during hospitalization. To identify predictors of use of coercive measures, both patients’ sociodemographic and clinical characteristics and centre-related characteristics were tested in a multivariate logistic regression model, controlled for countries’ effect.Results
The frequency of the use of coercive measures varied significantly across countries, being higher in Poland, Italy and Greece. Patients who received coercive measures were more frequently male and with a diagnosis of psychotic disorder (F20–F29). According to the regression model, patients with higher levels of psychotic and hostility symptoms, and of perceived coercion had a higher risk to be coerced at admission. Controlling for countries’ effect, the risk of being coerced was higher in Poland. Patients’ sociodemographic characteristics and ward-related factors were not identifying as possible predictors because they did not enter the model.Conclusions
The use of coercive measures varied significantly in the participating countries. Clinical factors, such as high levels of psychotic symptoms and high levels of perceived coercion at admission were associated with the use of coercive measures, when controlling for countries’ effect. These factors should be taken into consideration by programs aimed at reducing the use of coercive measures in psychiatric wards. 相似文献10.